Tocilizumab (RoActemra®) is a humanized anti human IgG1 monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.

PPS has generated considerable experience in the analysis of different originator batches as well as multiple variants of biosimilars of Tocilizumab.

We have established an analytical program according to the ICH Q6B guidance, including the method setup, validation of customer specific methods and release testing.

This package includes different assays for protein quantification and characterizing the protein primary structure and secondary structure, as well as detailed analysis of N-glycosylation and protein modification, including the detailed look for the C-and N-terminal heterogeneity of the heavy chain and the incomplete cleavage of the signal sequence from the N-terminus if the light chain.

 

Your contact for Tocilizumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com